![]() |
|
|
Vol. 30, Issue 2, 212-219, February 2002
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas
| |
Abstract |
|---|
|
|
|---|
Organic cation transporters (OCTs) are responsible for excretion of cationic substances into urine. Tissue OCT expression may be important for the disposition and excretion of xenobiotics. Therefore, OCT1, OCT2, OCT3, OCTN1, and OCTN2 mRNA levels were measured in adult rat tissues and rat kidney tissue at various stages of development from day 0 to 45. OCT1 mRNA expression was highest in kidney and spleen, moderate in skin, and low in the gastrointestinal tract, brain, lung, thymus, muscle, and prostate. OCT2 mRNA levels were highest in kidney, with low expression in other tissues, and with renal OCT2 levels being approximately 4 times higher in males than that in females. In gonadectomized males, OCT2 mRNA levels were attenuated to female levels, suggesting a role for testosterone in OCT2 expression. OCT3 was moderately expressed in kidney and was highest in blood vessel, skin, and thymus. OCTN1 was expressed in most of the tissues examined, with relatively higher expression in kidney and ileum and lower levels in thymus. Lastly, OCTN2 was expressed abundantly in kidney and ileum, moderately in large intestine, dorsal prostate, bladder, duodenum, and cerebellum, and minimally in thymus, spleen, and cerebral cortex. Renal OCT1, OCTN1, and OCTN2 mRNA levels increased gradually from postnatal day 0 through day 45 in both genders. Renal OCT2 levels remained the same in males and females through day 25 and then dramatically increased only in male kidney after day 30. In summary, OCT mRNA was detected primarily in kidney, and the high level of renal OCT expression may explain why the kidney is a target organ for xenobiotics with cationic properties.
| |
Introduction |
|---|
|
|
|---|
The
target-organ toxicity for any given xenobiotic is dependent on its
absorption, distribution, metabolism, and excretion. In addition to the
capacity for phase I and II metabolism, the body's ability to absorb
and excrete foreign chemicals is an important determinant for the
toxicity of different types of compounds. Specifically, the organic
cation transporters are responsible for the uptake of prototypical
organic cations, such as tetraethylammonium (TEA2), secretion of endogenous amines, such as
dopamine, and cationic xenobiotics, such as antihistamines and
antiarrhythmics (Zhang et al., 1998
; Burckhardt and Wolff, 2000
). To
date, five different rat OCTs have been identified: OCT1, OCT2, OCT3,
OCTN1, and OCTN2.
OCT1, OCT2, and OCT3 are membrane-potential-driven transporters and are
localized to the basolateral membrane of renal tubules (Urakami et al.,
1998
; Karbach et al., 2000
; Sugawara-Yokoo et al., 2000
). In rats, the
highest OCT1 mRNA expression is in kidney, with detectable expression
in liver and intestine (Grundemann et al., 1994
), whereas detectable
OCT1 mRNA expression in humans is localized to liver (Gorboulev et al.,
1997
; Zhang et al., 1997
). Similarly, OCT2 is highly expressed in
kidney, with no detectable transcripts in other organs in both rats and
humans (Okuda et al., 1996
; Gorboulev et al., 1997
). Within the kidney,
OCT2 is detected on the basolateral membrane of the S2 and S3 segments of proximal tubules located in the medullary rays (Karbach et al.,
2000
; Sugawara-Yokoo et al., 2000
). In rats, OCT3 mRNA levels seem to
be highest in placenta and are detectable in kidney, intestine, heart,
brain, and lung (Kekuda et al., 1998
). Within the kidney, OCT3 is
localized to the cortical region and is detected in the proximal and
distal convoluted tubules and within Bowman's capsule (Wu et al.,
2000b
).
Unlike OCT1 to 3, OCTN1 and OCTN2 (CT2) have functional characteristics
that suggest they are proton antiporters localized to the apical
membrane (Tamai et al., 1997
; Yabuuchi et al., 1999
). OCTN1 can
transport TEA, and this transport can be inhibited by a variety of
compounds, such as cimetidine, procainamide, and verapamil (Yabuuchi et
al., 1999
; Wu et al., 2000a
). In rats, the tissue distribution of OCTN1
is somewhat similar to that in humans. Rat OCTN1 mRNA levels are
highest in liver and kidney, moderate in intestine, skin, and lung, and
low (but detectable) in brain, testis, and thymus (Wu et al., 2000a
).
Both rat and human OCTN2 transport the zwitterion, carnitine, and TEA
(Sekine et al., 1998
; Wu et al., 1998b
, 1999
). Its transport of
carnitine can be inhibited by organic cations, such as TEA, choline,
and cimetidine, as well as carnitine derivatives, such as
acetyl-l-carnitine, propionyl-L-carnitine, and
palmitoyl-DL-carnitine (Wu et al., 1999
).
Interestingly, human OCTN2 can transport
-lactam antibiotics because
they contain quaternary nitrogens, and this transport phenomenon is of
pharmacological relevance (Ganapathy et al., 2000
). In rats, OCTN2 mRNA
content is highest in testis, kidney, and colon, with moderate
expression in small intestine, liver, brain, and placenta, and is low
or nondetectable in skeletal muscle, brain, lung, and heart (Sekine et
al., 1998
).
The branched DNA (bDNA) signal amplification assay is a quantitative
assay that can be used to measure mRNA content for a specific gene in a
similar format to an enzyme-linked immunosorbent assay with
linear amplification resulting in luminescence. This assay has been
described in detail for the detection of several cytochromes P450
(Hartley and Klaassen, 2000
). At this time, the tissue distribution of
rat OCT mRNA expression and the consequences of gender and/or age on
OCT expression have not been resolved. Thus, the objectives of the
described studies were to determine 1) the tissue distribution of OCT
expression in approximately 20 tissues from male and female rats and 2)
whether OCT mRNA expression is changed with age.
| |
Materials and Methods |
|---|
|
|
|---|
Animals. Male and female Sprague-Dawley rats (0-60 days old and gonadectomized adults) were purchased from Sasco Laboratories, Inc. (Kingston, NY). Animals were housed in a temperature-, light-, and humidity-controlled environment in hanging cages with hardwood chips. The rats were fed Laboratories Rodent Chow W (Harlan Laboratories, Madison, WI) ad libitum.
RNA Extraction. Total tissue RNA was extracted using RNAzolB reagent (Tel-Test, Inc., Friendswood, TX) according to the manufacturer's protocol. RNA integrity was confirmed by formaldehyde agarose gel electrophoresis before analysis by the bDNA signal amplification assay (Quantigene bDNA signal amplification kit; Bayer Diagnostics, East Walpole, MA).
bDNA Signal Amplification Assay.
OCT mRNA was measured using the bDNA assay (Quantigene bDNA signal
amplification kit) with modifications (Hartley and Klaassen, 2000
). Rat
OCT gene sequences of interest were accessed from GenBank (Table
1). Multiple oligonucleotide
probe sets (containing capture, label, and blocker probes) specific to
a single mRNA transcript (i.e., OCT1, 2, 3, N1, and N2) were designed
using Probe Designer software v1.0, and probes were designed
with a Tm of approximately 63°C,
enabling hybridization conditions to be held constant (i.e., 53°C)
during each hybridization step and for each probe set. Every probe
developed in Probe Designer was submitted to the National Center for
Biotechnological Information (NCBI, Bethesda, MD) for nucleotide
comparison by the basic logarithmic alignment search tool (BLASTn) to
ensure minimal cross-reactivity with other known rat sequences and
expressed sequence tags. Oligonucleotides with a high degree of
similarity (
80%) to other rat gene transcripts were eliminated from
the probe set design. The nucleotide sequence and function for all of
these probes are given in Table 1.
|
Statistics.
Data from ontogeny studies was analyzed using a two-way analysis of
variance followed by a Duncan's multiple range posthoc test. Asterisks
represent a statistical difference (p
0.05) between genders.
| |
Results |
|---|
|
|
|---|
Tissue Distribution of Rat OCT1, OCT2, OCT3, OCTN1, and OCTN2 mRNA Content. Initially, the mRNA content of OCT1 to 3, OCTN1, and OCTN2 was determined in 20 tissues using tissue RNA pooled from five animals (day 60) of each gender (data not shown). Data from these studies indicated that only OCT2 mRNA levels in kidney significantly differed with gender, and because OCT1, OCT3, OCTN1, and OCTN2 mRNA expression did not differ greatly between genders, only RNA from individual male tissues was analyzed for mRNA content for these genes.
OCT1 mRNA levels were highest in kidney, skin, spleen, and liver and were lowest in stomach (Fig. 1). Skin OCT1 mRNA expression was approximately 42%, liver OCT1 expression was 16%, and stomach expression was 1% of that present in kidney. Relative to kidney, OCT1 mRNA expression was low in the small and large intestine (intestinal OCT1 expression was approximately 7 to 12% of renal OCT1 expression) and brain (cerebellum and cerebral cortex OCT1 expression was approximately 6% of that detected in kidney). Similarly, relatively low OCT1 mRNA levels were detected in lung, thymus, spleen, heart, blood vessel, muscle, bladder, and prostate.
|
hepatic, thymic, and bladder tissue had approximately 2% of
the OCT2 mRNA present in male kidney and 9% of that detected in female
kidney. For all other tissues examined, OCT2 mRNA expression was, at
most, approximately 2% of renal OCT2 in males and 8% of renal OCT2 in females.
|
|
|
|
Developmental Changes in Kidney OCT mRNA Content. The kidney was selected to determine changes in OCT expression with development because OCT mRNA levels were generally highest in kidney (except for OCT3). Total RNA from four to five male and female rats was analyzed by the bDNA signal amplification assay to determine whether OCT expression changes over time from the newborn stage (day 0) through adulthood (day 45).
Indeed, the relative levels of OCT1 mRNA in kidney significantly increased with age by approximately 4.5-fold from day 0 to 45 (Fig. 6, upper panel). At day 45, OCT1 mRNA levels in female kidney were 30% higher than that present in male and comparable to that present in adult male kidney.
|
|
Renal OCT2 Expression in Gonadectomized Rats. In Fig. 2, OCT2 mRNA levels were significantly higher in male rat kidney than that in female kidney, and to evaluate this difference further, studies were conducted to determine the effect of gonadectomy on OCT2 expression. Consistent with the tissue distribution studies, OCT2 mRNA expression was significantly higher in kidneys from intact adult male than that present in kidneys from intact female rats (Fig. 8). However, in gonadectomized males OCT2 transcript levels decreased by approximately 50% of that present in intact male kidney, which was similar to levels detected in female kidney. Ovariectomy had no effect on OCT2 mRNA levels in female kidney.
|
| |
Discussion |
|---|
|
|
|---|
To date, five OCTs have been cloned from rat (Burckhardt and
Wolff, 2000
). Although most studies have documented the OCT mRNA content in some rat tissues, their tissue expression pattern has not
been thoroughly characterized in a quantitative manner, and postnatal
developmental changes in OCT mRNA expression in kidney have not been
evaluated. The bDNA assay is a highly sensitive method that detects
gene-specific transcripts in a quantitative manner. It has been used to
detect human immunodeficiency virus (Rouet et al., 2001
), hepatitis B
(Enomoto et al., 2001
), and cytochrome P450 isoforms (Hartley and
Klaassen, 2000
). Hence, this methodology was used to assess the
expression of OCTs in approximately 20 different tissues from adult
rats and in kidneys from postnatal day-0 through day-45 rats.
The present study demonstrated that rat OCT1 mRNA is predominantly
expressed in kidney, with moderate expression in liver, skin, and
spleen, and low expression in the other tissues examined. This work
agrees with previous reports that document high OCT1 mRNA expression in
rat kidney, with relatively lower expression in liver, even lower
expression in intestine, and nondetectable expression in skeletal
muscle, heart, and lung (Grundemann et al., 1994
; Wu et al., 1998b
).
OCT1 transcripts have been detected in intestine and colon but not in
spleen (Grundemann et al., 1994
). In our study, it was detected in
spleen with somewhat lower expression in small and large intestine.
Possible explanations for this inconsistency are that the Northern cDNA
or oligo probe used to originally document OCT1 expression may likely
detect other rat OCT isoforms and the bDNA assay can be a more
sensitive detection method than Northern analysis. Moreover, the
predominant OCT1 expression in rat kidney differs from human OCT1
expression, which is highest in liver (Zhang et al., 1997
). This
species difference may indicate that the rat is not a good model for
examining the disposition of OCT1 substrates. Because OCT1 was highest
in kidney, the ontogeny of OCT1 expression was performed using kidney
RNA from postnatal day-0 through day-45 rats. OCT1 mRNA expression
increased gradually from neonatal stages to adulthood in both males and
female kidney. Because OCT1 is localized to the basolateral membrane
(Urakami et al., 1998
; Karbach et al., 2000
) and it mediates the
removal of organic cations from blood into kidney and liver, both
organs may be susceptible to toxic organic cations that are substrates for OCT1. Furthermore, because OCT1 levels are lower in neonates than
that present in adults, xenobiotics that are OCT1 substrates may be
excreted more slowly in neonates, and this decreased capacity of
neonates for OC secretion may result in increased half-lives and blood
levels of cationic xenobiotics with narrow therapeutic to toxicity margins.
Our tissue distribution studies indicated that OCT2 mRNA is present in
high levels in kidney, with very low expression in the other tissues.
These findings agree with a study that detected an OCT2 message in
kidney and not in other tissues (Okuda et al., 1996
). Furthermore, the
predominant expression of OCT2 in rat kidney is analogous to human
expression of OCT2 mRNA, which is also primarily expressed in kidney
(Gorboulev et al., 1997
). Renal OCT2 levels dramatically increased
after day 25 in males, but a similar increase in female kidney was not
observed, and renal OCT2 levels in gonadectomized adult male rats were
substantially lower than that present in kidneys from intact males.
Together, these data suggest that OCT2 mRNA expression in kidney may be regulated by male steroid sex hormones. Our studies agree with articles
that document increased renal OCT2 mRNA, protein expression, and OC
uptake in male and female kidneys from rats treated with testosterone
(Urakami et al., 1999
, 2000
). This gender difference in OCT2 expression
supports an early finding that identified greater uptake of the organic
cation TEA in renal cortical slices from male rats compared with female
rats (Bowman and Hook, 1972
). The marked increase in kidney OCT2 mRNA
levels in males after day 25 suggests that there is an increase in
testosterone levels before day 25. In fact, there is evidence to
support this theory because it has been reported that serum
testosterone levels in male rats increase steadily from day 23 through
day 64 (Monosson et al., 1999
). Thus, it is imperative to identify
whether gender differences in OCT2 expression can cause differences in
OC distribution or toxicity to the kidney. There is evidence that this
may be true for the putative OCT2 substrate and nephrotoxicant
cisplatin (Pan et al., 1999
). Younger rats (age, 10-15 days) are less
susceptible to cisplatin-induced nephrotoxicity and have lower renal
platinum concentrations than that found in adult kidney following
cisplatin exposure (Appenroth and Braunlich, 1984
; Jongejan et al.,
1986
). Furthermore, renal platinum concentrations and cisplatin-DNA
adducts are higher in males than that in females following cisplatin
exposure (Reed et al., 1987
). The difference in OCT2 expression between young and adult rats and between genders may explain these earlier findings. It is unknown at this time if there is a gender difference in
OCT2 content in human kidney. Thus, if OCT2 is also differentially expressed in human kidney as it is in rat kidney, drugs that are OCT2
substrates may have very different excretion kinetics in females and
males, as well as for children versus adults.
In our studies, OCT3 mRNA levels were highest in blood vessel, skin,
and thymus
all tissues not known to express OCT3. Similar to
previously published data from Northern blots (Kekuda et al., 1998
; Wu
et al., 1998a
), OCT3 mRNA was low in liver, with detectable transcripts
in kidney and intestine. Relative to blood vessel, skin, and thymus,
renal OCT3 mRNA levels were low. Thus, changes in OCT3 expression
between different ages or genders may not result in significant changes
in OC distribution to kidney. Furthermore, the relative renal
expression of OCT3 compared with OCT1 or OCT2 would suggest that OCT3
might be less involved in OC uptake across the basolateral membrane if
functional OCT1 and OCT2 transporters are present.
OCTN1 has been identified as a bidirectional pH-dependent transporter
with affinity for organic cations, such as pyrilamine, verapamil,
quinidine, and quinine (Yabuuchi et al., 1999
). OCTN1 mRNA levels were
highest in kidney; however, this expression was not predominant, and
moderate OCTN1 mRNA levels were detected in liver, intestine, brain,
heart, spleen, and skin. These data agree with a previous article that
documents high OCTN1 mRNA expression in rat kidney, liver, and small
intestine and low expression in thymus and stomach (Wu et al., 2000a
).
Renal OCTN1 levels increased steadily with age, with significantly
higher OCTN1 mRNA levels in adult kidney. Humans also express high
levels of OCTN1 in kidney like that observed for rat; however, human
OCTN1 is minimally expressed in mature liver tissue, whereas OCTN1 mRNA
is moderately expressed in adult rat liver (Tamai et al., 1997
).
Because it is thought that OCTN1 is localized to the apical membrane
(Yabuuchi et al., 1999
), it is hypothesized to aid in the secretion of
organic cations from the tubule epithelia into the lumen. Thus, in
humans, if OCTN1 expression in kidney increases with age, the secretion of drug substrates for OCTN1 may also differ between children and
adults. This could be of important clinical significance because several OCTN1 substrates are antiarrhythmic drugs (Yabuuchi et al.,
1999
; Wu et al., 2000a
).
Furthermore, transcript levels of the carnitine transporter OCTN2 were
highest in kidney, ileum, and large intestine, with low expression in
thymus, spleen, and cerebral cortex, and this finding agrees with a
previous study that detected strong mRNA expression of OCTN2 in rat
kidney followed by mRNA expression in intestine and low expression in
spleen, muscle, and brain (Sekine et al., 1998
). However, our studies
found that OCTN2 mRNA was expressed moderately in testes, whereas
Sekine et al. (1998)
detected high OCTN2 mRNA expression in testes.
Like OCTN1, renal OCTN2 mRNA levels also increased gradually with age.
These data support clinical findings that document an age-related
decrease in total urine carnitine content (millimoles of carnitine/mole
of creatinine) from 0 to 5 years to 5 to 12 years or adulthood (de
Sousa et al., 1990
). Renal OCTN2 is thought to be responsible for
carnitine reabsorption and the reabsorption of other compounds
structurally similar to carnitine, such as
-lactam antibiotics
(Ganapathy et al., 2000
). A high capacity for reabsorption of certain
types of OCs may predispose the kidney to the accumulation of toxicants that are OCTN2 substrates. For example, the high expression of OCTN2 in
day-45 adult kidney compared with day-0 neonatal kidney may explain
previous findings that older rats and rabbits are more susceptible to
cephaloridine-induced nephrotoxicity and accumulation of renal
cephaloridine (Wold et al., 1977
; Goldstein et al., 1986
).
In summary, the most OCTs are predominantly expressed in kidney (except OCT3), and renal expression of OCTs seems to increase with age. The high expression of OCTs in kidney may explain previous findings with regard to differences in accumulation or toxicity of some compounds that are OCT substrates. However, additional studies must be performed to determine the tissue expression of OCT proteins and OCT protein levels correspondingly increasing with age in kidney. Further studies designed to identify the relationship between OCT expression and activity for age- or gender-related differences in the nephrotoxicity or bioavailability of various compounds may aid in the development of more effective therapeutic strategies.
| |
Acknowledgments |
|---|
The authors would like to thank Ning Li and Susan Buist for their technical assistance.
| |
Footnotes |
|---|
Received August 13, 2001; accepted November 9, 2001.
1 Present address: Department of Drug Metabolism, Merck Research Laboratories, Rahway, NJ 07065.
A.L.S., N.J.C., D.P.H, and T.M.L. were supported by National Institutes of Health Grant ES-09649.
Dr. Curtis Klaassen, Department of Pharmacology, Toxicology, and Therapeutics, 3901 Rainbow Boulevard, Kansas City, KS 66160. E-mail: cklaasse{at}kumc.edu
| |
Abbreviations |
|---|
Abbreviations used are: TEA, tetraethylammonium; OCT, organic cation transporter; bDNA, branched DNA; RLU, relative light units; OC, organic cation.
| |
References |
|---|
|
|
|---|
-Lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
J Biol Chem
275:
1699-1707This article has been cited by other articles:
![]() |
K. K. Filipski, W. J. Loos, J. Verweij, and A. Sparreboom Interaction of Cisplatin with the Human Organic Cation Transporter 2 Clin. Cancer Res., June 15, 2008; 14(12): 3875 - 3880. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Koch, B. Konig, G. I. Stangl, and K. Eder PPAR{alpha} Mediates Transcriptional Upregulation of Novel Organic Cation Transporters-2 and -3 and Enzymes Involved in Hepatic Carnitine Synthesis Experimental Biology and Medicine, March 1, 2008; 233(3): 356 - 365. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. G. Sipes, G. A. Knudsen, and R. K. Kuester The Effects of Dose and Route on the Toxicokinetics and Disposition of 1-Butyl-3-methylimidazolium Chloride in Male F-344 Rats and Female B6C3F1 Mice Drug Metab. Dispos., February 1, 2008; 36(2): 284 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Gasser, C. A. Lowry, and M. Orchinik Corticosterone-Sensitive Monoamine Transport in the Rat Dorsomedial Hypothalamus: Potential Role for Organic Cation Transporter 3 in Stress-Induced Modulation of Monoaminergic Neurotransmission. J. Neurosci., August 23, 2006; 26(34): 8758 - 8766. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Alnouti, J. S. Petrick, and C. D. Klaassen TISSUE DISTRIBUTION AND ONTOGENY OF ORGANIC CATION TRANSPORTERS IN MICE Drug Metab. Dispos., March 1, 2006; 34(3): 477 - 482. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tahara, H. Kusuhara, M. Chida, E. Fuse, and Y. Sugiyama Is the Monkey an Appropriate Animal Model to Examine Drug-Drug Interactions Involving Renal Clearance? Effect of Probenecid on the Renal Elimination of H2 Receptor Antagonists J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1187 - 1194. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Groves, W. B. Suhre, N. J. Cherrington, and S. H. Wright Sex Differences in the mRNA, Protein, and Functional Expression of Organic Anion Transporter (Oat) 1, Oat3, and Organic Cation Transporter (Oct) 2 in Rabbit Renal Proximal Tubules J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 743 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mancinelli, A. M. Evans, R. L. Nation, and A. Longo Uptake of L-Carnitine and Its Short-Chain Ester Propionyl-L-carnitine in the Isolated Perfused Rat Liver J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 118 - 124. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Gorboulev, N. Shatskaya, C. Volk, and H. Koepsell Subtype-Specific Affinity for Corticosterone of Rat Organic Cation Transporters rOCT1 and rOCT2 Depends on Three Amino Acids within the Substrate Binding Region Mol. Pharmacol., May 1, 2005; 67(5): 1612 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ishiguro, A. Saito, K. Yokoyama, M. Morikawa, T. Igarashi, and I. Tamai TRANSPORT OF THE DOPAMINE D2 AGONIST PRAMIPEXOLE BY RAT ORGANIC CATION TRANSPORTERS OCT1 AND OCT2 IN KIDNEY Drug Metab. Dispos., April 1, 2005; 33(4): 495 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Sung, K.-H. Yu, J.-S. Park, T. Tsuruo, D.-D. Kim, C.-K. Shim, and S.-J. Chung SATURABLE DISTRIBUTION OF TACRINE INTO THE STRIATAL EXTRACELLULAR FLUID OF THE RAT: EVIDENCE OF INVOLVEMENT OF MULTIPLE ORGANIC CATION TRANSPORTERS IN THE TRANSPORT Drug Metab. Dispos., March 1, 2005; 33(3): 440 - 448. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Augustine, R. J. Markelewicz Jr., K. Boekelheide, and N. J. Cherrington XENOBIOTIC AND ENDOBIOTIC TRANSPORTER MRNA EXPRESSION IN THE BLOOD-TESTIS BARRIER Drug Metab. Dispos., January 1, 2005; 33(1): 182 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Cundy, R. Branch, T. Chernov-Rogan, T. Dias, T. Estrada, K. Hold, K. Koller, X. Liu, A. Mann, M. Panuwat, et al. XP13512 [({+/-})-1-([({alpha}-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to Gabapentin, and Transport by Intestinal Solute Transporters J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 315 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Cundy, T. Annamalai, L. Bu, J. De Vera, J. Estrela, W. Luo, P. Shirsat, A. Torneros, F. Yao, J. Zou, et al. XP13512 [({+/-})-1-([({alpha}-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: II. Improved Oral Bioavailability, Dose Proportionality, and Colonic Absorption Compared with Gabapentin in Rats and Monkeys J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 324 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wright, K. K. Evans, X. Zhang, N. J. Cherrington, D. S. Sitar, and W. H. Dantzler Functional map of TEA transport activity in isolated rabbit renal proximal tubules Am J Physiol Renal Physiol, September 1, 2004; 287(3): F442 - F451. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Cherrington, A. L. Slitt, N. Li, and C. D. Klaassen LIPOPOLYSACCHARIDE-MEDIATED REGULATION OF HEPATIC TRANSPORTER mRNA LEVELS IN RATS Drug Metab. Dispos., July 1, 2004; 32(7): 734 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Grover, D. Buckley, A. R. Buckley, and W. Cacini Reduced Expression of Organic Cation Transporters rOCT1 and rOCT2 in Experimental Diabetes J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 949 - 956. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Kharasch, C. Hoffer, T. G. Altuntas, and D. Whittington Quinidine as a Probe for the Role of P-Glycoprotein in the Intestinal Absorption and Clinical Effects of Fentanyl J. Clin. Pharmacol., |